Expand KPTI Menu
KPTI MENU

KPTI Stock Summary and Trading Ideas (Karyopharm Therapeutics | NASDAQ:KPTI)

Charts for Today's Stock Price and Implied Volatility in Karyopharm Therapeutics

Stock Price & Volume | Full Chart

30-Day Implied Volatility | IV30 Full Chart

Trade Ideas for Best Option Strategies for KPTI by Theoretical Edge and Win Rates

Sentiment

Trading Statistics

Key Ratios

Karyopharm Therapeutics (KPTI) Frequently Asked Questions

What does Karyopharm Therapeutics do?

Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.

What symbol and exchange does Karyopharm Therapeutics shares trade?

Karyopharm Therapeutics trades on the NASDAQ stock market under the symbol KPTI.

What is Karyopharm Therapeutics stock price doing today?

As of March 4, 2025, KPTI stock price declined to $6.37 with 373,860 million shares trading.

What is Karyopharm Therapeutics's Beta?

KPTI has a beta of 0.84, meaning it tends to be less sensitive to market movements. KPTI has a correlation of 0.03 to the broad based SPY ETF.

How much is Karyopharm Therapeutics worth?

KPTI has a market cap of $53.61 million. This is considered a Micro Cap stock.

How much money does Karyopharm Therapeutics make?

Last quarter Karyopharm Therapeutics reported $31 million in Revenue and -$3.60 earnings per share. This fell short of revenue expectation by $-5 million and exceeded earnings estimates by $.45.

What is the highest and lowest price Karyopharm Therapeutics traded in the last 3 year period?

In the last 3 years, KPTI traded as high as $129.45 and as low as $5.95.

What are the top ETFs holding Karyopharm Therapeutics?

The top ETF exchange traded funds that KPTI belongs to (by Net Assets): VTI, VXF, IWC, CNCR.

Is Karyopharm Therapeutics (KPTI) a good investment?

KPTI has underperformed the market in the last year with a price return of -64.2% while the SPY ETF gained +13.9%. KPTI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.6% and -31.1%, respectively, while the SPY returned -4.2% and -5.4%, respectively.

What are the support and resistance levels for Karyopharm Therapeutics (KPTI)?

KPTI support price is $6.74 and resistance is $7.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KPTI shares will trade within this expected range on the day.